Background {#Sec1}
==========

Tissue engineering is an interdisciplinary field of research and clinical applications, which focuses on restoration of impaired function and morphology of tissues and organs by repair, replacement, or regeneration. It uses a combination of several technological approaches beyond traditional transplantation and replacement therapies. The key components of these approaches are using of cells, scaffolds, and bioactive factors.

Bone is a specialized connective tissue that is being continuously remodeled throughout life. However, many complex clinical conditions such as large traumatic bone defects, osteomyelitis, tumor resection, or skeletal abnormalities can impair normal bone healing. Bone tissue engineering is required for regenerating tissue from these conditions. Studies on the mechanisms of physiological, pathological skeletal development and fracture healing have provided a wealth of information towards potential methods for regulating osteoblast proliferation and differentiation to regenerate bone.

Here, we focus on one of the main components of tissue engineering, bioactive factors, especially fibroblast growth factors (FGFs) and their roles in bone regeneration.

FGF signaling in skeletal formation has been demonstrated by identification of gain-of-function mutations in human FGF receptor (FGFR) genes in craniosynostosis and dwarfism patients and skeletal phenotypes in genetically modified mice for FGFs and FGFRs \[[@CR1]\]. FGFRs are transmembrane tyrosine kinase receptors that belong to the immunoglobulin (Ig) superfamily consisting of extracellular, transmembrane, and intracellular tyrosine kinase domains. Binding of FGFs to FGFRs activates intracellular downstream signaling pathways such as RAS-MAP and PI3K-AKT \[[@CR2]\]. The FGFR family consists of four members, FGFR1 to FGFR4. Among the four FGFRs, skeletal mutations have been found in FGFRs1--3 expressed in the osteoblast cell lineage. Most of the mutations are point mutations, and distinct mutation sites result in different syndromes \[[@CR1]\]. Some of the mutations have been introduced into mice and confirmed to affect skeletal development.

FGFs and bone regeneration {#Sec2}
==========================

The mammalian FGF family contains 22 members. Some of them are intracellular FGFs (iFGFs), FGFs 11--14, which are expected to function without binding to FGFRs. FGF19 (FGF15 for mice), FGF21, and FGF23 are hormone-like FGFs which act in an endocrine manner in postnatal life. All other FGFs have high affinity to heparin and act in a paracrine manner by binding to the four receptors with different levels of affinities \[[@CR3]--[@CR5]\]. The roles of various FGFs are compiled in Table [1](#Tab1){ref-type="table"}. Skeletal phenotypes after deletion of FGFs in mice are found in FGFs 2, 8, 9, 10, 18, and 23 \[[@CR6]\], which confirm the indispensable function of FGF/FGFR signaling in the process of osteogenesis. It is of note that FGF/FGFR signaling does not directly induce osteoblast differentiation but is known to modulate osteoblast differentiation. However, the exact mechanism of FGF/FGFR signaling in bone healing or regeneration has not been elucidated. Schmid et al. \[[@CR7]\] reported expression levels of different FGFs by reverse transcriptase polymerase chain reaction (RT-PCR) during normal healing of tibial fracture in mice. Throughout the healing process, FGFs 2, 5, and 6 were upregulated with different levels. FGF9 was highly expressed at the early stage of healing. FGFs 16 and 18 were transcribed at the late stage. Upregulation of FGFs 1 and 17 was delayed after callus formation. This study also identified concordance between the expression of the particular FGFs and their known receptors during different stages of fracture repair. Among three FGFRs expressed in the osteoblast cell lineage, FGFR3 showed the greatest change in expression levels. This study provided the idea of how FGFs work at the different stages of healing, which could be applied to bone regenerative therapy.Table 1List of FGFs and their various functionsSubfamilyFGFsManner of actionPrime functionsReferencesFGF1/2FGF1ParacrinePatterning of optical vesicle\[[@CR36]\]FGF2ParacrineNeuronal, skeletal, vascular tone; heart repair\[[@CR37]--[@CR39]\]FGF4/5/6FGF4ParacrineProliferation of inner cell mass\[[@CR40]\]FGF5ParacrineHair growth cycle regulator\[[@CR41]\]FGF6ParacrineRegulation of muscle regeneration\[[@CR42]\]FGF3/7/10/22FGF3ParacrineInner ear formation, regulation of tooth morphogenesis\[[@CR43], [@CR44]\]FGF7ParacrineModulation of hair growth, kidney development\[[@CR45], [@CR46]\]FGF10ParacrineRegulator of development of many organs such as brain, limb, lung, pancreas\[[@CR47], [@CR48]\]FGF22ParacrinePresynaptic organization in brain development, hair development\[[@CR49], [@CR50]\]FGF9/16/20FGF9ParacrineLung development, maintenance of stemness in nephrons, bone repair, mammalian sex determination\[[@CR51]--[@CR53]\]FGF16ParacrineHeart development\[[@CR54]\]FGF20ParacrineInner ear development, maintenance of stemness in nephrons\[[@CR52], [@CR55]\]FGF8/17/18FGF8ParacrineDevelopment of brain, limbs, cardiovascular system, craniofacial region\[[@CR56]--[@CR59]\]FGF17ParacrineBrain development\[[@CR60]\]FGF18ParacrineBone and cartilage development, lung development\[[@CR22], [@CR61]\]FGF11/12/13/14FGF11IntracrineSignalling functions during tooth development\[[@CR62]\]FGF12IntracrineUnclearFGF13IntracrineSignaling functions during tooth development\[[@CR62]\]FGF14IntracrineRegulation of neurotransmission of motor functions\[[@CR63]\]FGF15/19/21/23FGF15/19EndocrineRegulates hepatic glucose metabolism\[[@CR64]\]FGF21EndocrineLipid metabolism regulator\[[@CR65]\]FGF23EndocrinePhosphate and vitamin D metabolism\[[@CR66]\]The table shows the subfamilies of various FGFs, FGFs under each subfamily, the manner of action of each FGF, and their prime functions

Considering clinical applications, studies involving modification of FGF signaling by ligands are more practical compared to those involving modulating FGFRs. Animal studies revealed that the expression of FGFs 8 and 10 is required for the early stage of limb development, which suggests that they are not directly involved in osteogenesis. Among FGFs which change their expression levels during bone fracture healing, FGF1 protects the osteoblast cell lineage from cell death \[[@CR8]\]. FGF5 is associated with the hair follicle cycle. FGF6 is involved in muscle regeneration and those events that occur during the healing process. Therefore, in this review, we chose FGFs 2, 9, and 18 to discuss about their properties and applications for bone regeneration.

FGF2 {#Sec3}
====

FGF2 is the most common FGF ligand that is being used in the regenerative medicine field including bone regeneration. It has been well known that FGF2 is a critical component of maintenance of many kinds of stem cell cultures \[[@CR9]\]. Stabilization of FGF2 levels in a culture medium using polyesters of glycolic and lactic acid (PLGA) microspheres as a FGF2 release controller successfully improved the expression of stem cell markers, increased stem cell numbers, and decreased spontaneous differentiation \[[@CR10]\].

*FGF2*-deleted mice showed a significant decrease in bone mass and bone formation without gross abnormalities. Bone marrow stromal cells (BMSCs) from the *FGF2* ^−/−^ mice demonstrated decreased osteoblast differentiation, which can be partially rescued by addition of exogenous FGF2 in vitro \[[@CR11]\]. Furthermore, *FGF2* ^−/−^ BMSC-derived osteoblasts displayed a marked reduction in inactive phosphorylated glycogen synthase kinase-3 (GSK-3) as well as a significant decrease in Dkk2 mRNA, which plays important roles in osteoblast differentiation. These results suggested that FGF2 is an endogenous, positive regulator of bone mass \[[@CR12]\]. In contrast, non-specific overexpression of FGF2 (Tg-*FGF2*) in mice exhibits a dwarf phenotype with impaired bone mineralization and osteopenia \[[@CR13]\]. Addition of FGF2 into a culture medium of a mouse osteoblast-like cell line, MC3T3-E1, activated cell proliferation and suppressed mineralization \[[@CR14]\]. In this study, treatment of the cells with FGF10 as an experimental control did not show any effects. These observations suggested that FGF2 could work in both directions for osteogenesis promotion and inhibition. It is important to elucidate conditions for positive and negative osteogeneses.

FGF9 {#Sec4}
====

*FGF9* ^−/−^ mice showed disproportionate shortening of the proximal skeletal elements (rhizomelia), which suggests that FGF9 promotes chondrocyte hypertrophy and vascularization of the cartilage anlagen \[[@CR15]\]. A missense mutation of *FGF9* in mice resulted in decreased heparin binding, which caused elbow-knee synostosis \[[@CR16]\]. A similar mutation was also found in humans \[[@CR17]\]. *FGF9* ^+/−^ mice did not seem to have a particular phenotype. However, bone healing of a 1-mm unicortical defect was impaired with decreased levels of neovascularization and osteoclast recruitment. This condition was rescued by exogenous addition of FGF9 (2 μg) with collagen sponge but not by exogenous FGF2 application \[[@CR18]\]. These reports elucidated the specific functions of FGF9 in bone healing.

Bone healing of a 1-mm unicortical defect in diabetic model mice (*db*/*db*) was significantly delayed with decreased levels of osteogenesis marker expressions. Treatment of FGF9 with collagen sponge to the defect in the *db*/*db* mice induced better bone healing \[[@CR19]\]. Treatment with FGF9-soaked collagen sponge to mouse circular calvarial bone defects of a diameter of 2 mm showed sufficient bone regeneration in postnatal day 7 (P7) mice but not in postnatal day 60 (P60) mice \[[@CR20]\]. Addition of FGF9 with various concentrations into dexamethasone-containing media for inducing osteogenesis of BMSCs and dental pulp stem cells resulted in stimulation of proliferation but not differentiation \[[@CR21]\].

FGF18 {#Sec5}
=====

Deletion of FGF18 in mice resulted in delayed suture formation, reduced osteoblast lineage cell proliferation, delayed osteoblast differentiation, and perinatal death. The long bones of *FGF18* ^−/−^ mice showed reduced osteoblast differentiation but increased chondrocyte proliferation and differentiation. These results suggested that FGF18 demonstrated a positive effect on osteogenesis by enhancing cell proliferation and differentiation but a negative effect on chondrogenesis \[[@CR22], [@CR23]\]. However, it was also proposed that FGF18 transduced the signal through FGFR3 to enhance cartilage formation \[[@CR24]\].

In vitro analysis on mesenchymal stem cells (MSCs) derived from the bone marrow suggested that FGF18 enhanced osteoblast differentiation by activation of FGFR1 or FGFR2 signaling \[[@CR25]\]. They also showed that overexpression of FGF18 by lentiviral infection or direct addition of FGF18 into the culture medium could induce the expression of osteoblast marker genes in C3H10T1/2 fibroblastic cells. Treatment of FGF18 on rat-derived MSCs under a differentiation-inducing condition showed elevated expression of osteoblast differentiation markers and mineralization \[[@CR26]\]. Low-dose FGF18 treatment with bone morphogenetic protein 2 (BMP2)-dependent osteogenic induction of MC3T3-E1 cells enhanced mineralization whereas high-dose treatment inhibited the process (unpublished observation of Sachiko Iseki). FGF18-soaked heparin-coated acrylic beads accelerated osteoblast differentiation in mouse fetuses by upregulating the expression of BMP2 in osteoblast cell lineage cells \[[@CR27]\]. In accordance with the above reports, FGF18 application with BMP2 in cholesteryl group- and acryloyl group-bearing pullulan (CHPOA) nanogels stabilized BMP2-dependent bone regeneration of critical-sized bone defects on mouse calvarium \[[@CR28]\].

Application of FGFs in bone regeneration {#Sec6}
========================================

The above discussions suggest that although FGFs do not have osteoinductive property, they function as an accelerator of osteogenesis under the appropriate conditions. It is possible that FGF2 and FGF9 work on proliferation of osteoblast cell lineage as well as induction of angiogenesis, and FGF18 functions in promotion of osteoblast differentiation. Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} show some of the in vivo experiments in which FGFs were applied to non-critical- and critical-sized bone defects for bone healing, respectively. Further applications of FGFs have been elaborated by Du et al. and Gothard et al. \[[@CR29], [@CR30]\].Table 2Application of different FGFs in non-critical-sized bone defect in vivo modelsGrowth factorDoseIn vivo modelCarrierInvestigationsEffectReferencesFGF2200 μgMonkey ulna fractureInjectable gelatin hydrogelBone mineral content and mechanical propertiesAccelerates fracture healing and prevents nonunion\[[@CR67]\]FGF22.5 μgRat periodontal defect (2 × 2 × 1.7 mm)Injectable calcium phosphate cementHistology and histomorphometry of boneIncreased periodontal regeneration\[[@CR68]\]FGF250 μgRat calvarial defect (4-mm diameter)PLGA/β-TCPHistomorphometry of boneEnhanced bone regeneration\[[@CR69]\]FGF250 μg/mlRat calvarial defect (5-mm diameter)Collagen and nano-bioactive glass hybrid membraneHistomorphometry of boneAccelerated bone regeneration\[[@CR70]\]FGF245 μgRabbit femoral condyle (4-mm diameter and 6 mm long)Hydrogel polymerBone mass and microarchitectureEnhanced bone regeneration\[[@CR32]\]FGF210 μgRat tibia (2-mm diameter, 4 mm long)Titanium implantBone histomorphometrySynergistically enhanced new bone formation\[[@CR71]\]Melatonin100 mg/kg i.p.FGF2200, 400, or 800 μgHuman tibia (high tibial osteotomy)Gelatin hydrogelRadiographic assessment of boneDose dependently accelerated bone union\[[@CR72]\]FGF2100 μgRabbit femoral condyle (10 mm^2^ × 5 mm depth)Interconnected porous calcium hydroxyapatite ceramicBone histomorphometryDecreases lamellar bone formation, increases vascularization and osseointegration\[[@CR73]\]FGF20, 25, or 250 ngRat calvarial defect (3.5-mm diameter)PLGA/gelatinRadiological, histological, and biochemical examinationLow-dose administration enhanced the degree of calcification and ALP activity\[[@CR74]\]BMP20.1 mg/mlFGF92 μgMouse tibia (1-mm defect)Collagen spongeBone histomorphometryEnhances angiogenesis and bone regeneration\[[@CR19]\]The table shows the various growth factors and their combinations used for regeneration of non-critical-sized defects, their dose, the site of application, the carrier used for the application, and the investigations through which the effects of bone healing have been studied*i.p.* intraperitoneal injection Table 3Application of different FGFs in critical-sized bone defect in vivo modelsGrowth factorDoseIn vivo modelCarrierInvestigationsEffectReferencesFGF25 ngMouse calvarial defect (3.5-mm diameter)Col-HA/PEG hydrogelMicro CT and histology of boneEnhanced bone regeneration\[[@CR34]\]BMP22 μgFGF210 ng, 100 μg, and 1 μgRat mandibular defect (5-mm diameter)Collagen spongeRadiological and histological examinationPromotes osteogenesis\[[@CR75]\]FGF2200 μgBeagle dog periodontal defect (6 × 5 mm: vertical × horizontal)β-TCPBone histomorphometryEnhances formation of new bone and cementum\[[@CR76]\]FGF180.5 μgMouse calvaria (3-mm diameter)CHPOA/hydrogelMicro CT assessment of boneSynergistically enhanced new bone formation\[[@CR28]\]BMP20.5 μgFGF2 or FGF9 or FGF18250 ng (P7 mice) or 2.5 μg (P60 mice)Mouse calvaria defect (2-mm diameter)Collagen spongeMicro CT assessment of boneAll FGF ligands promote healing rate in P7 mice. Only FGF18 promotes healing rate in P60 mice\[[@CR20]\]The table shows the various growth factors and their combinations used for regeneration of critical-sized defects, their dose, the site of application, the carrier used for the application, and the investigations through which the effects of bone healing have been studied

Systemic or subcutaneous injections of FGF2 could enhance osteogenesis. However, it was shown that systemic injections of FGF2 caused adverse extraskeletal effects \[[@CR31]\]. Therefore, local administration has been chosen as a more preferable method for applying bioactive factors. FGF2 has been used for inducing angiogenesis and enhancing osteogenesis in non-critical-sized bone defects by activating proliferation of osteoblast cell lineages. FGF9 is also suggested to be involved in angiogenesis by controlling VEGFa expression \[[@CR18]\]. As long as osteogenesis is taking place to recover the bone defect, FGF2 can support or even enhance the healing. Recent studies suggest that high-dose FGF2 inhibits progression of osteoblast differentiation \[[@CR20], [@CR32], [@CR33]\] (also unpublished observation of Sachiko Iseki) and low concentration of FGF2 enhanced osteogenesis \[[@CR33], [@CR34]\]. In contrast, it is likely that high-dose FGF18 can promote osteoblast differentiation in vivo \[[@CR20], [@CR28]\], while FGF18 treatment in vitro inhibits mineralization \[[@CR14]\].

Kang et al. developed a sequential delivery system with fiber scaffolds in which FGF2 was released first and then FGF18 \[[@CR35]\]. Applying this scaffold to rat calvarial critical-sized bone defects resulted in better bone volume and density, although the amount of FGFs applied to the defect was not clear. This study suggested that it is critical to control the amount or release speed of soluble factors for the bone regeneration process.

Conclusions {#Sec7}
===========

FGFs play an important role in the development and regeneration of various tissues. In this article, we have summarized the prime functions of all FGFs, and further, we have discussed elaborately about FGFs 2, 9 and 18, which play a major role in bone regeneration. We have also discussed about different carrier systems for FGF delivery in different animal models for bone regeneration. With the ongoing advancements in the field of cellular and molecular biology, we could expect that more detailed functioning of FGF/FGFR will be elucidated. Further, with the advent of novel carriers and protein delivery systems, it could be possible that the spatio-temporal release of FGFs can be controlled precisely as needed. This would improve our understanding and help us to clinically translate the use of FGFs to achieve effective bone regeneration.
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:   Fibroblast growth factor
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:   Fibroblast growth factor receptor
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:   Glycogen synthase kinase-3
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:   Intracellular fibroblast growth factor
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:   Immunoglobulin
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:   Vascular endothelial growth factor A

β-TCP
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